The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023 to US$ 129.46 billion by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.

Key factors driving the market growth are the rising adoption of drug delivery systems for disease management propels the transmucosal drug delivery systems market growth. Additionally, the development of new drug molecules and biological formulations is contributing to market growth. However, the concerns associated with biocompatibility and limited drug candidates hamper the market growth.

Market Trends of the Transmucosal Drug Delivery Systems Market:

Integration of nanotechnology into transmucosal drug delivery systems enables the design of nanoscale drug carriers that can enhance the physicochemical properties of the drug and target delivery to the mucosal tissues. Several strategies have been suggested for loading drug-containing nanoparticles (NPs) onto the buccal mucosa for local and systemic applications. There has been significant interest in developing mucoadhesive buccal formulations, particularly hydrogel composites that incorporate mucoadhesive films containing NPs. For instance, a review article published by the Multidisciplinary Digital Publishing Institute (MDPI) in August 2020 discussed various applications of silica NPs in transmucosal drug delivery. The article concluded that silica nanoparticles have shown promise as effective drug nanocarriers for transmucosal drug delivery. This is because they can be easily prepared using simple methods and offer control over particle size and shape, high drug loading capacity, and controlled drug delivery. By synthesizing different types of silica NPs with various functional groups, it is possible to achieve even greater drug delivery efficacy.

Therefore, such technological advancements in the drug delivery systems are expected to bring new market trends in the coming years.

Transmucosal Drug Delivery Systems Market: Segmental Overview

The transmucosal drug delivery systems market is segmented on the basis of systems and end user.

By systems, the market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR during 2023-2031. The buccal route of drug administration is a noninvasive, topical method in which drugs are held or applied in the buccal cavity, i.e., the space between the cheek and gums. After their absorption through the oral mucosa, drugs enter the systemic circulation through the jugular vein, bypassing the intestines. This drug administration has many advantages, such as rapid onset of action and a higher bioavailability than the oral route. This method also evades first-pass metabolism, which protects it from degradation in the gastrointestinal (GI) tract.

In terms of end user, the transmucosal drug delivery systems market is segmented into healthcare facilities, homecare settings, and others. The healthcare facilities segment held the largest market share in 2023. The market growth of this segment can be attributed to the availability of better facilities and skilled physicians in hospitals. The homecare settings segment is anticipated to register the highest CAGR during 2023-2031.

Transmucosal Drug Delivery Systems Market: Geographical Overview

The scope of the transmucosal drug delivery systems market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In terms of revenue, North America held the largest transmucosal drug delivery systems market share in 2023. The US dominates the market in this region. This can be attributed to the increasing cases of chronic diseases such as diabetes, asthma, and cardiac diseases as well as the growing number of product launches by key players.